Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for FT536, an innovative multiplexed-engineered CAR NK cell therapy targeting MICA and MICB stress proteins in solid tumors. The multi-center Phase 1 clinical trial aims to evaluate the treatment's safety and effectiveness as both monotherapy and in combination with monoclonal antibodies. FT536 features a high-affinity CD16 receptor and modified IL-15 components, designed to enhance NK cell activity and persistence in tumor environments. The trial will include various advanced solid tumor types.

Fate Therapeutics (FATE) reported interim Phase 1 data for its FT596 program, focusing on relapsed/refractory B-cell lymphoma. Results show that 5 of 6 patients achieved an objective response, with 4 obtaining a complete response after a single 900 million cell dose combined with rituximab. In total, 13 of 19 patients responded to a single dose of FT596 at lower doses. The treatment was well-tolerated, with no serious adverse events reported. A two-dose regimen is being initiated to assess further efficacy. The company will host a virtual investor event for detailed insights.

Fate Therapeutics presented positive clinical data from its Phase 1 study of FT516 at the 63rd ASH Annual Meeting. The investigational NK cell therapy showed promising results with 6 of 10 CAR T-naïve patients continuing to respond at a median follow-up of 9.1 months. Additionally, 3 of 8 previously treated patients achieved a complete response. FT516 was well-tolerated, with no major safety concerns reported. The FDA granted FT516 RMAT designation, promoting expedited development for relapsed/refractory DLBCL. The company initiated dose-expansion cohorts at 900 million cells per dose, aiming to enroll diverse patient populations.

Fate Therapeutics, Inc. (NASDAQ: FATE) announced a virtual event titled “B-cell Lymphoma Franchise Update” on December 14, 2021, at 8:00 AM ET. The event will present interim Phase 1 clinical data for the FT516 and FT596 programs targeting relapsed/refractory B-cell lymphomas. Access to the live webcast will be available on the company's website, with an archive posted two hours post-event. Fate Therapeutics specializes in programmed cellular immunotherapies leveraging its induced pluripotent stem cell (iPSC) platform, holding over 350 patents to support its innovative treatments.

Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, will present at several upcoming investor conferences. Notable events include the Jefferies London Healthcare Conference on November 18, 2021, the Piper Sandler 33rd Annual Healthcare Conference on November 23, 2021, and the Evercore ISI HealthCONx Conference on November 30, 2021. These presentations will be available on demand, and a live webcast will be accessible via the company's website. Fate Therapeutics aims to enhance cancer treatments with innovative cell therapies.

Fate Therapeutics announces its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting with a selected abstract showcasing preclinical data from its FT538 and FT573 programs. Key findings indicate FT538's efficacy against glioblastoma cells and its combination with an NK cell engager targeting B7-H3. A live audio webcast will take place on November 15, 2021, highlighting its emerging iPSC-derived NK cell pipeline. The company emphasizes its innovative iPSC platform's potential to enhance cancer treatment through engineered cell therapies.

Fate Therapeutics announced the enrollment of patients in Phase 1 clinical studies for FT538 and FT576 targeting relapsed/refractory multiple myeloma. Interim data from FT596 and FT516 for relapsed/refractory lymphoma show promising results with 71% and 73% objective response rates (ORR) respectively. Both FT596 and FT516 demonstrate differentiated safety profiles with low-grade adverse events. Financial results reveal total revenue of $14.2 million for Q3 2021, alongside R&D expenses of $53.1 million and cash reserves of $803.6 million as of September 30, 2021.

Fate Therapeutics announced that several presentations on their induced pluripotent stem cell (iPSC) product platform have been accepted for the 63rd American Society of Hematology Annual Meeting. The presentations will include updated clinical data for their cancer immunotherapies FT596 and FT516. FT596 achieved a 71% objective response rate in relapsed/refractory B-cell lymphoma patients, while FT516 achieved a 73% objective response rate. The treatments were well tolerated with no reported adverse events of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GVHD).

Fate Therapeutics (NASDAQ: FATE) announced a conference call for November 4, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and corporate updates. Shareholders can join the call by dialing (877) 303-6235 domestically or (631) 291-4837 internationally, using conference ID 9459084. The live audio webcast will be available under the Events section of the company's website. Fate Therapeutics focuses on developing first-in-class cellular immunotherapies for cancer, leveraging its proprietary induced pluripotent stem cell technology.